Weight gain and diabetes with "second-generation" antipsychotic drugs [3]

Medical Journal of Australia

Volumn 182, Issue 12, 2005, Pages 652-653

  Firestone, Andrew ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

AUSTRALIA; BODY WEIGHT DISORDER; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; HUMAN; HYPERGLYCEMIA; LETTER; OBESITY; PRESCRIPTION; PSYCHOSIS; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; STATISTICS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION; HUMANS; OBESITY; PREDIABETIC STATE; WEIGHT GAIN;

EID: 21644486402     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb06860.x     Document Type: Letter

References (5)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
2. Graham KA, Perkins DO, Edwards LJ, et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; 162: 118-123.
3. Holzer L, Paiva G, Halfon O. Quetiapine-induced weight gain and escitalopram. Am J Psychiatry 2005; 162: 201-202.
4. Lambert TJR, Chapman LH, on behalf of the Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544-548.
5. Firestone A. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement [letter]. Med J Aust 2004; 182: 310.